Clinical efficacy of tocilizumab in patients with active rheumatoid arthritis in real clinical practice
Open Access
- 22 August 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Rheumatology International
- Vol. 30 (8), 1041-1048
- https://doi.org/10.1007/s00296-009-1095-0
Abstract
The previous clinical studies have demonstrated tocilizumab monotherapy to be highly effective in rheumatoid arthritis (RA). The objectives of the present article are to report the efficacy and safety of tocilizumab in patients with active RA in real clinical practice. In total, 61 patients with RA were treated with tocilizumab. Any comorbidities they had, especially infections, were treated thoroughly before they were given the drug. We provided guidance on infection control and prevention. Mean age of the patients was 60.9 ± 12.4 years, and their mean disease duration 10.9 ± 9.2 years. The patients remained on steroids, methotrexate, and tacrolimus as before, but were taken off any other drugs they had been using prior to the treatment. Mean of the 28-joint disease activity score using erythrocyte sedimentation rate was 4.75 ± 1.15 initially and fell to 2.21 ± 0.97 after two doses (n = 50). After four doses, the remission rate was 83.8% (31/37). All patients responded well to the therapy and there was no decrease in the efficacy of tocilizumab during the treatment. Even in the real clinical setting, treatment with tocilizumab can rapidly induce remission in RA in a high proportion of patients and is generally safe and well tolerated. Tocilizumab would seem to be promising as a first-line choice for the treatment of RA.Keywords
This publication has 17 references indexed in Scilit:
- Periodontal Therapy Reduces the Severity of Active Rheumatoid Arthritis in Patients Treated With or Without Tumor Necrosis Factor InhibitorsThe Journal of Periodontology, 2009
- Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension studyAnnals Of The Rheumatic Diseases, 2008
- Evidence that cytokines play a role in rheumatoid arthritisJCI Insight, 2008
- Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapyModern Rheumatology, 2008
- Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safetyBMC Musculoskeletal Disorders, 2008
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialThe Lancet, 2008
- Oral infection, hyperglycemia, and endothelial dysfunctionOral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, 2008
- Dystrophin deficiency in canine X-linked muscular dystrophy in Japan (CXMDJ) alters myosin heavy chain expression profiles in the diaphragm more markedly than in the tibialis cranialis muscleBMC Musculoskeletal Disorders, 2008
- Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritisArthritis & Rheumatism, 2007
- Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumabAnnals Of The Rheumatic Diseases, 2007